Systemic Lupus Erythematosus

Pooled data from three randomized, placebo-controlled, multi-center Phase III clinical trials in female patients with systemic lupus erythematosus show prasterone significantly reduced the risk of autoimmune flare and breast cancer, and reduced the risk of death from any cause by 80%.  To learn more, visit www.prastera.com.

PRASTERA® brand prasterone is now available for partnering outside the United States.   To learn more, Contact Us